UNSPSC 51141554: Dinazafone

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 411OG24QOU. European Medicines Agency schedules Dinazafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07191MIG. Dinazafone generally arises in the molecular formula C20H21CLN2O2. The term DINAZAFONE is an International Non-Proprietary Name or INN. DINAZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule dinazafone under HS 29242995 and SITC 51479. As of Q4 2014, DINAZAFONE remains the US FDA Preferred Term for this commodity. Dinazafone bears US NLM identifiers UMLS ID C1880337 and NCI Concept Code C65411. SMILES: CLC1CC(C(N(C(=O)CNCC(=C)C)C)CC1)C(=O)C1CCCCC1.

UNSPSC 51141554 Dinazafone (Commodity) describes pharmaceutical products and drug-related supplies that state and local governments procure for public health, emergency response, and community health initiatives. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for opioid crisis response, generic pharmaceuticals and over-the-counter products through cooperative purchasing frameworks, and exploring direct-to-manufacturer prescription programs to manage pharmacy benefit costs and improve fulfillment efficiency. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances coordinating across participating jurisdictions. Scope ranges from discrete emergency-response purchases of naloxone units to broad-based pharmaceutical supply agreements leveraging authorized wholesaler networks and requiring compliance with FDA manufacturing practices, Drug Supply Chain Security Act standards, and federal procurement regulations.

Recent activity clusters in Florida and Minnesota-led cooperative purchasing, with the Texas Health and Human Services Commission exploring direct pharmaceutical manufacturer relationships. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring vendor compliance with E-Verify, drug-free workplace certification, and potential FEMA funding compliance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota, Oregon, and other participating jurisdictions, requiring vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and comply with cGMP and DSCSA standards. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for implementing direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, signaling exploratory procurement intent ahead of formal RFP issuance.